Printer Friendly

CELL GENESYS PROMOTES KRISZTINA ZSEBO, PH.D., TO VICE PRESIDENT OF PRODUCT DEVELOPMENT

 FOSTER CITY, Calif., July 27 /PRNewswire/ -- Cell Genesys Inc. (NASDAQ: CEGE) announced today the election of Krisztina M. Zsebo, Ph.D., 37, to the newly created position of vice president of product development. Zsebo joined the company last year as director of research, following an eight-year career with Amgen Inc.
 "Dr. Zsebo's demonstrated talent in coordinating the efforts of multi-disciplinary product development teams is a strong asset for Cell Genesys as our research programs move forward toward human clinical trials," said Stephen A. Sherwin, M.D., president and chief executive officer. "She has an impressive track record of helping to advance basic scientific discoveries from the laboratory to the clinic."
 During the past year, Zsebo has been responsible for initiating and coordinating initial product development activities at Cell Genesys, as well as coordinating the company's research program in the cell therapy area. Cell Genesys' current focus in the cell therapy area involves the production of anti-HIV T cells for the treatment of HIV infection in persons with AIDS. The company plans to begin initial human clinical trials of this potential product next year.
 Zsebo joined Amgen in 1984, where she most recently served as a research scientist and associate director of product development for hematopoietic stem cell factor, a protein that stimulates blood cell growth. Her scientific team isolated and characterized the protein, which entered clinical trials last year. Prior to that, she was a research scientist on the team that brought granulocyte colony- stimulating factor into clinical trials.
 Zsebo was awarded a doctorate in biochemistry from the University of California at Berkeley. She earned a master's in biochemistry and biophysics from Oregon State University and a bachelor's degree from the University of Maryland. Zsebo is an author on more than 50 published scientific papers.
 Cell Genesys is a leader in the application of gene targeting technology to the development of human therapeutic products. Gene targeting is a cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, therapeutic protein products and human monoclonal antibody products.
 -0- 7/27/93
 /CONTACT: Stephen A. Sherwin, M.D., president and chief executive officer of Cell Genesys, 415-358-9600, ext. 212/
 (CEGE)


CO: Cell Genesys Inc. ST: California IN: MTC SU: PER

TM-MC -- SF007 -- 6252 07/27/93 13:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 27, 1993
Words:405
Previous Article:MBNA REPORTS 20.1 PERCENT INCREASE IN NET INCOME; 19 PERCENT GROWTH IN MANAGED LOANS; 1.6 MILLION NEW CARDHOLDERS; ANNOUNCES QUARTERLY DIVIDEND
Next Article:THERAPEUTIC DISCOVERY CORP. REPORTS SECOND QUARTER RESULTS
Topics:


Related Articles
DR. KRISZTINA ZSEBO JOINS CELL GENESYS AS DIRECTOR OF RESEARCH FOR CELLULAR THERAPY
TSI CORPORATION LICENSES GENE TARGETING TECHNOLOGY FROM CELL GENESYS, INC.
ADVANCED TISSUE SCIENCES AND CELL GENESYS TO COLLABORATE IN DEVELOPING A UNIVERSAL 'FULL-THICKNESS' SKIN TRANSPLANT PRODUCT
CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES
CELL GENESYS ADDS TWO KEY PRODUCT DEVELOPMENT DIRECTORS
KATHLEEN GLAUB JOINS CELL GENESYS AS CHIEF FINANCIAL OFFICER
CELL GENESYS NAMES EXECUTIVE TEAM FOR NEW SUBSIDIARY, ABGENIX
CELL GENESYS ANNOUNCES EXECUTIVE PROMOTIONS
JAMES GOWER JOINS CELL GENESYS BOARD OF DIRECTORS
Abgenix Board Appoints Kurt Leutzinger as Chief Financial Officer

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters